BioXell SpA is an R&D-based biopharmaceutical company, its core strategy is to discover and develop novel therapeutics targeting the immune system and controlling the causes of acute and chronic inflammatory diseases, treating infection and cancer. The research in BioXell’s pipeline stems from two technology platforms based on vitamin D3 analogues and the TREM receptor system. Three of BioXell’s vitamin D3 analogues are BXL-628 for treating benign prostatic hyperplasia, BXL-353 and BXL-490 for treating secondary hyperparathyroidism.